Redefining Obesity Care: Targeting the Skin as an Immuno-Neuro- Endocrine Organ for Sustainable Weight Loss
Time: 11:30 am
day: Pre-Conference Day
Details:
- Targeting skin SCD1 offers a unique drug approach to obesity, resulting in systemic efficacy without systemic drug exposure. The mechanism to increase energy expenditure without involving brown fat or UCP-1
- This unique approach to obesity provides the distinct advantages of preferential fat reduction while preserving lean muscle mass, low COGs, facile dosing and high patient compliance
- Lipidio’s drug provides an alternative for patients who are unresponsive to or intolerant of existing therapies, for use in combination as a drug sparing strategy to reduce GLP-1side effects and post GLP-1 as a safe way to prevent weight re-bound
Speakers:
